1. Home
  2. MRKR vs CPHI Comparison

MRKR vs CPHI Comparison

Compare MRKR & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.52

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

HOLD

Current Price

$0.55

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
CPHI
Founded
1999
N/A
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
26.3M
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
MRKR
CPHI
Price
$1.52
$0.55
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
132.2K
8.2K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
N/A
EPS
N/A
N/A
Revenue
N/A
$4,144,268.00
Revenue This Year
N/A
N/A
Revenue Next Year
$936.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$0.50
52 Week High
$4.07
$2.60

Technical Indicators

Market Signals
Indicator
MRKR
CPHI
Relative Strength Index (RSI) 51.74 41.32
Support Level $1.34 $0.53
Resistance Level $1.55 $0.66
Average True Range (ATR) 0.09 0.05
MACD -0.01 -0.01
Stochastic Oscillator 44.91 24.12

Price Performance

Historical Comparison
MRKR
CPHI

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Share on Social Networks: